Chevallier Patrice, Mahe Beatrice, Garand Richard, Talmant Pascaline, Harousseau Jean-Luc, Delaunay Jacques
Department of Hematology, Centre Hospitalier Universitaire, Nantes, France.
Service d'Hématologie Clinique, Centre Hospitalier Universitaire, 9 quai Moncousu, BP1005, 44093, Nantes cedex 01, France.
Int J Hematol. 2008 Sep;88(2):209-211. doi: 10.1007/s12185-008-0123-2. Epub 2008 Aug 1.
Gemtuzumab Ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin-g1. It was developed at the end of the nineties as 90% of the leukemic blast population of patients with acute myeloid leukaemia (AML) express the CD33 surface antigen (Dinndorf et al. [1] Blood 1986;67:1048-53). GO is currently approved in monotherapy for the treatment of CD33+ AML patients in first relapse, showing a 26% overall response rate and a median disease-free-survival of 5.2 months for responders (Larson et al. [2] Cancer 2005;104:1442-52). CD33 antigen expression is also observed at diagnosis (in 15% of cases) (Pui et al. [3] J Clin Oncol 1998;16:3768-73) or at relapse (Guglielmi et al. [4] Leukemia 1997; 11:1501-7) of acute lymphoblastic leukaemia (ALL), representing a potential cellular target for ALL patients. Case series have already demonstrated the efficacy of GO in children with relapsed CD33+ ALL with documentation of complete remission (CR) (Balduzzi et al. [5] Leukemia 2003;17:2247-8; Cotter et al. [6] Br J Haematol 2003;122:686-91; Zwaan et al. [7] Leukemia 2003;17:468-70). In the other hand, there is no report at our knowledge of the use of GO in the setting of adult CD33+ ALL patient. Here we report the case of a 30-year-old man with a refractory CD33+ ALL who received a salvage regimen combining chemotherapy + GO and achieved a transient CR.
吉妥单抗奥唑米星（GO）是一种与细胞毒性抗肿瘤抗生素刺孢霉素 - g1偶联的人源化抗CD33抗体。它于九十年代末研发，因为90%的急性髓系白血病（AML）患者的白血病原始细胞群表达CD33表面抗原（Dinndorf等人[1]《血液》1986年；67:1048 - 53）。GO目前被批准用于一线复发的CD33 + AML患者的单药治疗，显示出26%的总缓解率，缓解者的无病生存期中位数为5.2个月（Larson等人[2]《癌症》2005年；104:1442 - 52）。在急性淋巴细胞白血病（ALL）的诊断时（15%的病例）（Pui等人[3]《临床肿瘤学杂志》1998年；16:3768 - 73）或复发时（Guglielmi等人[4]《白血病》1997年；11:1501 - 7）也观察到CD33抗原表达，这代表了ALL患者的一个潜在细胞靶点。病例系列已经证明GO对复发的CD33 + ALL儿童有效，有完全缓解（CR）的记录（Balduzzi等人[5]《白血病》2003年；17:2247 - 8；Cotter等人[6]《英国血液学杂志》2003年；122:686 - 91；Zwaan等人[7]《白血病》2003年；17:468 - 70）。另一方面，据我们所知，尚无关于在成年CD33 + ALL患者中使用GO的报道。在此我们报告一例30岁难治性CD33 + ALL男性患者的病例，该患者接受了化疗 + GO联合的挽救方案并实现了短暂的CR。
